Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, October 25, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Tue, October 24, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Tejas Savant Maintained (ADPT) at Hold with Decreased Target to $10 on, Oct 24th, 2023
Tejas Savant of Morgan Stanley, Maintained "Adaptive Biotechnologies Corporation" (ADPT) at Hold with Decreased Target from $13 to $10 on, Oct 24th, 2023.
Tejas has made no other calls on ADPT in the last 4 months.
There is 1 other peer that has a rating on ADPT. Out of the 1 peers that are also analyzing ADPT, 0 agree with Tejas's Rating of Hold.
This is the rating of the analyst that currently disagrees with Tejas
- David Westenberg of "Piper Sandler" Maintained at Buy with Decreased Target to $13 on, Monday, October 16th, 2023
